TP53 and cancer: For example, a previous review from Pfoh et al. (2015) (190) proposed the development of a drug that would block interaction between MDM2 and USP7 in patients with cancer caused by hyperactivation of MDM2, thereby targeting MDM2 for degradation and stabilizing p53.